March 25, 2024

Population pharmacokinetic/pharmacodynamic target attainment analysis of IV fosfomycin for the treatment of MDR Gram-negative bacterial infections

Key Points

Key points are not available for this paper at this time.

Abstract

IV fosfomycin is used against MDR Gram-negative bacilli (GNB) but has dose-limiting side effects, especially in patients with impaired kidney function.

Bookmark

Cite This Study

Wangchinda et al. (Mon,) studied this question.

synapsesocial.com/papers/68e72652b6db6435876a062a https://doi.org/https://doi.org/10.1093/jac/dkae111

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat Gram-negative bacterial infections2021 · 17 citations
2Pharmacodynamics of Fosfomycin: Insights into Clinical Use for Antimicrobial Resistance2015 · 110 citations
3Prevalence of fosfomycin resistance and plasmid-mediated fosfomycin-modifying enzymes among carbapenem-resistant Enterobacteriaceae in Zhejiang, China2017 · 28 citations
4The need for robust validation for MDRD-based glomerular filtration rate estimation in various CKD populations2011 · 119 citations
5Current clinical use of intravenous fosfomycin in ICU patients in two European countries2019 · 63 citations

Bookmark